Targeting Cancer Metabolism to Improve Outcomes with Immune Checkpoint Inhibitors-Reference-Cited by-同舟云学术

Targeting Cancer Metabolism to Improve Outcomes with Immune Checkpoint Inhibitors

Published:2023-02-02 Issue:2 Volume:6 Page:91-102
ISSN:2590-017X
Container-title:Journal of Immunotherapy and Precision Oncology
language:en
Short-container-title:

Author:

Fatima Zainab¹,Abonofal Abdulrahman²,Stephen Bettzy³^ORCID

Affiliation:

1. 1 Department of Hospice and Palliative Care, Virginia Commonwealth University, Richmond, VA, USA

2. 2 Department of Medicine, Section of Hematology/Oncology, West Virginia University, Morgantown, WV, USA

3. 3 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Abstract

ABSTRACT Immune checkpoint inhibitors have revolutionized the treatment paradigm of several cancers. However, not all patients respond to treatment. Tumor cells reprogram metabolic pathways to facilitate growth and proliferation. This shift in metabolic pathways creates fierce competition with immune cells for nutrients in the tumor microenvironment and generates by-products harmful for immune cell differentiation and growth. In this review, we discuss these metabolic alterations and the current therapeutic strategies to mitigate these alterations to metabolic pathways that can be used in combination with checkpoint blockade to offer a new path forward in cancer management.

Publisher

Innovative Healthcare Institute

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://meridian.allenpress.com/innovationsjournals-JIPO/article-pdf/6/2/91/3216802/i2590-017x-6-2-91.pdf

Reference109 articles.

1. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020; 11: 3801.

2. El Osta B, Hu F, Sadek R, et al. Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol. 2017; 119: 1– 12.

3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646– 674.

4. Renner K, Singer K, Koehl GE, et al. Metabolic hallmarks of tumor and immune cells in the tumor microenvironment. Front Immunol. 2017; 8: 248.

5. Zhang W, Zhang SL, Hu XH, Tam KY. Targeting tumor metabolism for cancer treatment: is pyruvate dehydrogenase kinases (PDKs) a viable anticancer target? Int J Biol Sci . 2015; 11: 1390– 1400.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lactate-induced activation of tumor-associated fibroblasts and IL-8-mediated macrophage recruitment promote lung cancer progression;Redox Biology;2024-08

2. First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours;BMJ Oncology;2024-05

3. Insights on the Role of Polyphenols in Combating Cancer Drug Resistance;Biomedicines;2023-06-14